Preventing Recurrences: Classic and Modern Antiarrhythmic Drugs in Atrial FibrillationCastro Urda Víctor*, Toquero Ramos Jorge and Fernández Lozano Ignacio
Electrophysiology Unit, Hospital Universitario Puerta de Hierro Majadahonda (Madrid), Spain
- *Corresponding Author:
- Castro Urda
Unidad de Arritmias
Servicio de Cardiología
Hospital Universitario Puerta
de Hierro Majadahonda
C/Manuel de Falla, 128222
Majadahonda, Madrid, Spain
Tel: 91 191 66 44
E-mail: [email protected]
Received date: October 15, 2014; Accepted date: December 19, 2014; Published date December 22, 2014
Citation: Víctor CU, Jorge TR, Ignacio FL (2015) Preventing Recurrences: Classic and Modern Antiarrhythmic Drugs in Atrial Fibrillation. Cardiol Pharmacol 4:130. doi:10.4172/2329-6607.1000130
Copyright: © 2015 Víctor CU et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Medication for atrial fibrillation (AF) with antiarrhythmic drugs (AAD) has been in use for almost 100 years and today remains an essential part of the treatment in patients with this condition. The goals of drug treatment include reducing the number, duration and symptoms of atrial fibrillation episodes, reducing mortality and hospitalizations as well as improving the patients’ quality of life. AAD use is limited by adverse effects which include proarrhythmia, negative inotropic and non-cardiovascular toxicity. The efficacy of these drugs is limited, which means that there are other invasive options that are clearly more effective for symptomatic control of patients.